



International
Federation of
Pharmaceutical
Manufacturers &
Associations

Fédération
Internationale de
l'Industrie du
Médicament

Federación
Internacional de la
Industria del
Medicamento



News Release

IFPMA Leadership Transition

Search for New Director General Launched

Geneva, 30 April 2009 – The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) announced today that Ms. Alicia Greenidge has stepped down as Director General and will leave IFPMA in November 2009 in order to pursue other opportunities. She joined IFPMA in 2008 after a long distinguished career working for the United States Government.

During the search for a successor, Laurent Renaud, IFPMA's Director of Finance and Administration will be responsible for the day-to-day administrative operations of the organization. Mr. Renaud will be under the direction of Michael Boyd, Vice President of Public Affairs for Schering-Plough Corporation, who will serve as Acting Director General effective immediately.

In a statement, the IFPMA said, "The IFPMA Leadership is confident that Mike Boyd has the ability to lead IFPMA on an interim basis while we search for a new Director General. Mike is well-respected inside and outside of our industry and we are grateful for his willingness to take on this temporary assignment." Prior to working at Schering-Plough, Mr. Boyd worked for Pfizer, GE, and the United States House of Representatives. Mr. Boyd is also a licensed attorney.

IFPMA has retained Egon Zehnder International, a global executive search firm, to manage the search for a new Director General.

(ends)

About the IFPMA

The International Federation of Pharmaceutical Manufacturers & Associations is the global non-profit NGO representing the research-based pharmaceutical, biotech and vaccine sectors. Its members comprise 26 leading international companies and 44 national and regional industry associations covering developed and developing countries. The industry's R&D pipeline contains hundreds of new medicines and vaccines being developed to address global disease threats, including cancer, heart disease, HIV/AIDS and malaria. The IFPMA Clinical Trials Portal (www.ifpma.org/ClinicalTrials), the IFPMA's Ethical Promotion online resource (www.ifpma.org/EthicalPromotion) and its Developing World Health Partnerships information (www.ifpma.org/HealthPartnerships) help make the industry's activities more transparent. The IFPMA strengthens patient safety by improving risk assessment of medicines and combating their counterfeiting. It also provides the secretariat for the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).

For further information, please contact:

Guy Willis

Director of Communications

E-mail: g.willis@ifpma.org

Tel: +41 22 338 32 00

Fax: +41 22 338 32 99

Web: www.ifpma.org